According to the results of the ZUMA-7 clinical trial, the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe